| Full text | |
| Author(s): |
da Silva, Lais Teodoro
[1]
;
Pontillo, Alessandra
[2, 1]
;
da Silva, Wanessa Cardoso
[1]
;
de Almeida, Alexandre
[1]
;
da Silva Duarte, Alberto Jose
[1]
;
Oshiro, Telma Miyuki
[1]
Total Authors: 6
|
| Affiliation: | [1] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Med Invest Dermatol & Immunodeficiencies LIM, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Immunogenet Lab, Sao Paulo - Brazil
Total Affiliations: 2
|
| Document type: | Journal article |
| Source: | Immunotherapy; v. 5, n. 12, p. 1305-1311, DEC 2013. |
| Web of Science Citations: | 0 |
| Abstract | |
Aims: HIV-1 expanded in an allogenic system (Al-HIV) represents a cheaper and faster alternative to the autologous virus (Au-HIV) as an antigen in anti-HIV immunotherapy. In this study, chemically inactivated HIV-1 obtained through autologous or allogenic systems were compared. Patients \& methods: Au-HIV and Al-HIV obtained from cultures of peripheral blood mononuclear cells from 11 HIV+ individuals were tested for virus production, yield and time of culture, and their ability to elicit a specific immune response in vitro. Results: The allogenic system was more efficient than the autologous system. Dendritic cells pulsed with Au-HIV and Al-HIV presented a similar phenotypic profile, but only Al-HIV induced a significant increase in IFN-(+) lymphocytes. Conclusion: The use of an allogenic system displays several advantages in terms of cell manipulation, time and cost of culture, and immunogenicity. (AU) | |
| FAPESP's process: | 12/18879-6 - Characterization of dendritic cells used in an anti-HIV therapeutic vaccine clinical trial (Phase I/II) |
| Grantee: | Telma Miyuki Oshiro Sumida |
| Support Opportunities: | Regular Research Grants |